JPRN-jRCT2031220028招募中3 期
A randomized, Double-blind, Parallel-group Study of KAR in patients with head lice infestations that resistance to existing treatment
Ishii Norihisa0 个研究点目标入组 198 人开始时间: 2022年4月22日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 198
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 6month old 至 ot applicable（—）
- 性别
- All
入选标准
- •1. Patient is at least 6 months of age at time of consent
- •2. Patients with at least 1 live head lice and at least 5 head lice eggs present on scalp and/or hair
- •3. Diagnosed as having head lice infestations that resistance to topical Phenothrin 0.4% or topical Dimethylpolysiloxane 4%
- •4. Patients who are able to participate in visit2 observation, examination, and investigation on the same day by all same household members with head lice infestations or suspected
排除标准
- •1. Do not live in fixed dwelling
- •2. Patients with same household member who fulfill inclusion criteria 2 but do not fulfill other inclusion criteria
- •3. Unable to apply appropriate drugs by the person or the same adult household member
- •4. Patients used ivermectin oral agents, topical phenotrin, topical dimethylpolysiloxane, and other drugs that are expected to be effective against head lice from 7 days before Visit2 to Visit2
- •5. Patients who have had their head lice physically wiped out with a comb after obtaining consent
- •6. Patients who have had a haircut or chemical treatment of the hair (hair dyeing, permanent wave, hair straightening) after obtaining consent
研究者
相似试验
未知
1 期
A Study of RO4917523 Versus Placebo as Adjunctive Therapy in Patients With Major Depressive Disorder and an Inadequate Response to Ongoing Antidepressant TherapyJPRN-jRCT2080221839Hoffmann-La Roche Ltd, Chugai Pharmaceutical Co., Ltd.300
已完成
不适用
A Randomized, Double-blind, Parallel Group Study of the Safety and Effect on Clinical Outcome of Tocilizumab SC Versus Tocilizumab IV, in Combination With Traditional Disease Modifying Anti-rheumatic Drugs (DMARDs), in Patients With Moderate to Severe Active Rheumatoid Arthritis-M05M05PER-083-10F. HOFFMANN-LA ROCHE LTD.,24
进行中（未招募）
不适用
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-InhibitorAdult Rheumatoid Arthritis (RA)MedDRA version: 13.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2010-023587-40-GRF. Hoffmann-La Roche Ltd.700
已完成
不适用
Rosemary anti-stress main studyhealthy personJPRN-UMIN000047500Clinical Creative Co., Ltd44
撤回
3 期
A randomized, double-blind, parallel-group study of the reduction of signs and symptoms during treatment with tocilizumab versus adalimumab, both in combination with MTX, in patients with moderate to severe active rheumatoid arthritis and an inadequate response to treatment with only one TNF inhibitor.RA1000381610023213rheumatoid arthritisNL-OMON36590Roche Nederland B.V.15